Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.53 |
| ▸ | NPC1 | O15118 | 9/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2813042 | 1.00 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2MCHR1ALDH1A1 | |
| SCHEMBL417902 | 0.82 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL565748 | 0.82 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL417903 | 0.82 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL23530261 | 0.81 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL457981 | 0.80 | P4HTM (0.56) | SMN1; SMN2MCHR1ALDH1A1KMT2AP4HTM | |
| SCHEMBL21595797 | 0.79 | CHRNA3 (0.55) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL21596058 | 0.79 | CHRNA3 (0.55) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL21595800 | 0.79 | CHRNA3 (0.55) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2886641 | 0.78 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106349156-A | Pyridine-2-amides capable of being used as CB2 agonist | 霍夫曼-拉罗奇有限公司 | 2017-01-25 | — | — | CN | claimed |
| CN-103608332-B | Pyridine-2-amides useful as CB2 agonists | 霍夫曼-拉罗奇有限公司 | 2016-09-28 | — | — | CN | claimed |
| CN-106349156-B | It can be used as the pyridine -2- amides of CB2 agonist | 霍夫曼-拉罗奇有限公司 | 2018-12-11 | — | — | CN | disclosed |
| CN-106349156-A | Pyridine-2-amides capable of being used as CB2 agonist | 霍夫曼-拉罗奇有限公司 | 2017-01-25 | — | — | CN | disclosed |
| CN-103608332-B | Pyridine-2-amides useful as CB2 agonists | 霍夫曼-拉罗奇有限公司 | 2016-09-28 | — | — | CN | disclosed |
| CN-104854092-A | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE | 2015-08-19 | — | — | CN | disclosed |
| EP-2188273-B1 | SUBSTITUTED TETRA HYDRO NAPHTHALINES, METHOD FOR THEIR MANUFACTURE AND THEIR USE AS DRUGS | SANOFI SA (FR) | 2014-10-22 | — | — | EP | disclosed |
| US-20140088077-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | SANOFI (FR) | 2014-03-27 | — | — | US | disclosed |
| US-8609731-B2 | Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments | SANOFI (FR) | 2013-12-17 | — | — | US | disclosed |
| EP-2396298-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI (FR) | 2011-12-21 | — | — | EP | disclosed |
| US-20100249097-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| WO-2010092154-A1 | NOVEL SUBSTITUTED INDANES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088077-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | DHPS, CYP11B2, CYP11B1 | RAB9A 3214/4885NPC1 403/4885SMN1; SMN2 3949/4885 |
| US-20100249097-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | DHPS, CYP11B2, CYP11B1 | RAB9A 3214/4885NPC1 403/4885SMN1; SMN2 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.